A study to compare rosuvastatin which is administered daily in one group and on alternate days in the other group comparing the improvement of blood lipid profile and to compare the side effects
Phase 2
- Conditions
- Health Condition 1: E785- Hyperlipidemia, unspecified
- Registration Number
- CTRI/2024/05/067550
- Lead Sponsor
- George T Varghese
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients willing to give written informed consent.
2. Patients aged more than 18 and less than or equal to 65 years.
3. Treatment naive patients of dyslipidemia in low to moderate risk group as diagnosed by NCEP ATP III guidelines
Exclusion Criteria
1. Patients unwilling to give written informed consent.
2. Patients with a documented history of acute coronary syndrome, cerebrovascular accident, on-going angina.
3. Pregnant and lactating mothers.
4. Patients on co-existing medication which aggravate statin myopathy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Percentage reduction in LDL-C <br/ ><br>2. Changes in other lipid markers like total cholesterol, triglycerides, HDL-C <br/ ><br>Timepoint: 6 weeks
- Secondary Outcome Measures
Name Time Method umber and severity of adverse events reported by the patient at any time during the study.Timepoint: 6 weeks